Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.

Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting.

About the Boceprevir HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). SVR rates are not yet available for Part II of this study evaluating boceprevir with low-dose REBETOL (n=59) compared to contemporaneous control (n=16) as described above.

About Boceprevir Phase III Studies

Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected with HCV genotype 1. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders). The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... 30, 2014 According ... Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), ... Reagents], Application (Immunology, Oncology) & by End ... by MarketsandMarkets, provides a detailed overview of ... market trends, and strategies impacting the global ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 25, 2012 The Department of Justice, on behalf of ... consent decree of permanent injunction against generic drug manufacturer ... consent decree was filed against Ranbaxy Laboratories, Ltd., an ... N.J. Ranbaxy Labs., Dale Adkisson, senior vice president, head ...
... 2012  Covance Inc. (NYSE: CVD ) said ... repurchase of up to $300 million of its outstanding ... approximately 800,000 shares remaining under a previously-announced repurchase authorization ... common stock. Any purchases under this buyback would be ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4Covance Board Authorizes $300 Million Stock Buyback 2
(Date:9/30/2014)... UC Irvine immunologists reveals new information about how our ... that determines how the body,s ability to fight infection ... Immunology , neurology professor Dr. Michael Demetriou, postdoctoral scholar ... a critical mechanism underlying how T cells are created, ... cell is a type of blood cell called a ...
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... September 30, 2014 VisitandCare.com ... Turkey has gone up more than 79 percent in ... tourism company also reported total revenue tripled for its ... The company’s professional strategy has allowed them to partner ... designed for patient comfort and privacy — with state-of-the-art ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Regenerative Medicine Solutions Expanding 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... are reminded to protect their eyes and skin ... dangerous UV rays on and off the field, PINELLAS PARK, ... eagerly awaited time to enjoy outdoor sports and activities.,However, many forget ... practice outdoor sports -- particularly in the summer,-- are conscious of ...
... July 29 On October 30, millions of breast,cancer ... glasses in a "Toast to the Cure.", This ... by breast cancer to memorialize those friends and family ... the stories of,survivors, commending cause advocates, thanking supporters, and ...
... Despite Experiencing Leg Pain and ... Discomfort, ... legs -- force many embarrassed sufferers to cover up, even on,the hottest ... develop into serious health problems. According,to a new survey, many who suffer ...
... found that cerebral malaria is related to long-term cognitive impairment in ... current issue of the journal Pediatrics . , ... is a leading cause of death for children in sub-Saharan Africa. ... is one of the deadliest forms of malaria. It only takes ...
... ANNAPOLIS, Md., July 29 RiskWatch, Inc. announced ... RWSURVEY,available http://www.rwsurvey.com ., The web-based software allows ... surveys online and includes compliance surveys for:, ... PCI HIPAA Compliance BSA-AML ISO 27001 ...
... July 29 American Imaging Management (AIM), an,operating ... and leading imaging,benefit management and technology company with ... that it has reached an,agreement to provide diagnostic ... of Vermont (BCBSVT)., "As a company that ...
Cached Medicine News:Health News:Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans 2Health News:Video: A 'Toast to the Cure' Set for October 30 Breast Cancer Survivors 'Raise Your Glasses' 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 3Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 4Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:New Web-Based Compliance Program Released by RiskWatch 2Health News:American Imaging Management Partners with Blue Cross and Blue Shield of Vermont 2
... is the first hernia repair material ... operative contamination of the material. This ... preservative agents, silver carbonate and chlorhexidine ... colonization on the patch for up ...
... in 1958, Bard mesh has become the ... compared. Bard mesh was used by Dr. ... "tension-free" hernia repair many years ago. Lichtenstein ... ideal" substance for permanent reinforcement of hernia ...
... PerFix plug technique, recommended for the ... indirect and direct inguinal hernias, provides ... technique, requiring less overall dissection and ... repair technique. The result is increased ...
... is a compact, highly portable, single wavelength ... integrated StarPulse feature enables the treatment of ... leg and face, and pigmented surface lesions, ... used as a continuous wave laser for ...
Medicine Products: